Experimental HIV vaccine passes early safety check in small trial

NCT ID NCT03934541

Completed ⭐️ VACCINE ⭐️ Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 28 times

Summary

This early-stage trial tested a new HIV vaccine in 24 healthy adults to see if it is safe and triggers an immune response. The vaccine uses a liposome (a tiny fat bubble) to deliver a piece of the HIV virus. The study found no major safety concerns and measured the body's antibody response to the vaccine.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Alabama CRS

Birmingham, Alabama, 35294, United States
Brigham and Women's Hospital Vaccine CRS (BWH VCRS)

Boston, Massachusetts, 02115-6110, United States
Columbia P&S CRS

New York, New York, 10032-3732, United States
Fenway Health (FH) CRS

Boston, Massachusetts, 02215-4302, United States
New York Blood Center CRS

New York, New York, 10065, United States
Seattle Vaccine and Prevention CRS

Seattle, Washington, 98109-1024, United States

Conditions

Explore the condition pages connected to this study.

HIV INFECTIONS